Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

PHASE4CompletedINTERVENTIONAL

Enrollment

228

Participants

Timeline

Start Date

June 7, 2021

Primary Completion Date

December 23, 2022

Study Completion Date

December 23, 2022

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Insulin glargine (U300)

Pharmaceutical form:Solution for injection in a prefilled pen Route of administration: Subcutaneous

Trial Locations (2)

Investigational site Number 3560003, Jaipur

Investigational site Number 3560013, Nashik